Along with the emergence and development of translational biomedicine, more and more genetic information has been applied in clinical practice. In the recent decade, the discovery of genetic markers for cancer prognosis obtains increasing attentions and many methods have been developed. The "element" methods use one or two independent genes to judge the Boolean status of disease. The "set" methods use multiple genes markers as a whole to classify patients into different risks. And the advanced "sets" methods use a group of different sets of biomarkers in an assembling manner. Either the existed "set" or "sets" methods only concern positive correlations among genes. However, the negative regulation, negative feedback, and functional repression are actually the relevant clues in cancer studies. Therefore, in this paper, based on the integrative gene expression data organized as gene-time-sample data or gene-sample-source data, we propose to mine negative correlated gene sets (NCGSs) from multiple data sets, and use them along with the maximal positive correlated gene sets for prognosis classification. The experiment results suggest the promotions of cancer prognosis accuracy and meaningful pathogen relevance of gene markers by NCGS applications.
Introduction
Along with the emergence and development of translational biomedicine, more and more genetic information has been applied in clinical practice [1] . As specific genotype will be possible direct cause of phenotype, using genomic data to explain human disease becomes an important research field to build the bridge between inner and outer risk factors. Particularly, discovery of genetic markers for cancer prognosis obtains increasing attentions because they will help the physician to select the optimal personal treatment for each patient [2] .
In the recent decade, it has been a popular analysis method to find specific genes in disease samples as possible indicators of their clinical outcomes [3, 4, 5, 6, 7, 8] . The usage of pathogen genes in clinical outcome prediction can be from simple to complex according to different techniques. One kind is the "element" methods, which only use one or two independent genes to judge the Boolean status of disease. However, many researches have shown that single gene is usually not enough to reflect the mapping between genotype and phenotype of cancer samples. For example, in [3] Basham et al. analyzed the the mutation loci distribution of gene BRCA2 in the population and found that it does not display obvious clusters (Figure 1(a) , whereas the mutation of BRCA2 in a central portion, referred to as the ovarian cancer cluster region, was traditionally thought to play a dominant role in breast cancer.
In fact, several pathological stages can exist during the development of cancers, and many complex diseases should be contributed by lots of genes. So the "set" methods that find the multiple gene markers as a whole are proposed to classify patients into different risks. For examples, in the research of chemotherapy response prediction, Spentzos et al. have mined a group of 93 genes [4] , some of which have significant high expression in patients with response but low expression in patients without response, and the other genes have the inverse expression behavior (displayed in Figure 1 (b). However, the "set" methods still suffer the critical problem about their robustness. Different sets may be found to play the roles in the diagnosis or treatment of the complex diseases. For example, in the breast cancer research, Sotiriou et al. found that the overlap between their optimal survival list of 485 probe elements and the 231 genes in the van't Veer et al. prognostic gene set [2] consisted of only 11 unique genes [9] , which results that the physicians are confused to make the decision in their clinical applications. Furthermore, the set showing strong distinguishing ability on one data can not promise to always perform well on other data for the same kind of disease, which makes the set be less convincible to the clinicians. Therefore, the advanced "sets" methods using a group of different sets of biomarkers have been widely focused currently [6, 7, 8] . These methods can be further divided into two categories as sets-ensemble methods such as [6, 7] and setsenrichment methods such as [8] . Sets-ensemble methods usually ensemble multiple classifiers, and each of such classifier is still constructed by a single marker set. Therefore, they concern more about the robustness of final classifier rather than the involved genes. While sets-enrichment methods consider each set as a whole and use all sets to build the classification model. For (a) Biomarker element from [3] (b) Biomarker set from [4] (c) Biomarker sets (pathways) from [8] Figure 1: Examples of different categories of biomarker applications [3, 4, 8] example, in [8] , the pathway (containing with a set of genes) expression significance or activation degree has been used in cancer prognosis study where patients with good and bad prognosis show distinct pathway expression patterns (Figure 1(c) ).
Although the "sets" methods have increased the biomarker robustness to some extent, there are still some fundamental flaws when used in actual clinical applications. On one hand, current sets-ensemble methods concern more about the robustness of classifiers [7] rather than the involved genes. They usually provide few clues on the steady gene markers although they can achieve high accurate and robust classifiers [6] . However, the physicians indeed would be more interested in the robustness of involved genes but not the classifiers. On the other hand, the sets-enrichment methods try to generate the biomarkers by incorporating known functional gene groups into the enrichment analysis. However, The referred gene groups usually come from independent biomarker study or the known molecular pathway components, which originally only focus on positive correlations among genes. While, the negative regulation, negative feedback, and functional repression have already shown to be important mechanisms behind cancer [10] . In all, the robust negative correlation in genetic information should have its crucial role yet has been under-estimated in cancer researches.
Therefore, in order to share more benefits from genetic information for clinical applications, we propose to identify negative correlated gene sets (NCGSs) from multiple data sets (integrative gene expression data), and use them as markers to do prognosis classification. We first present an algorithm negEDSIA, based on EDISA method [11] , to mine NCGSs from multiple data sets. Then we adopt two different strategies to encode the gene sets for support vector machine (SVM) modeling according to the composition of the integrative data set, i.e., MMSE scores which we proposed recently for gene-time-sample data and functional enrichment P-values for gene-sample-source data. Experimental results show that both positive and negative correlated gene sets can actually co-exist, and the importing of NCGSs can provide more clues and enhance the accuracy of cancer prognosis.
Methods

Definition of the NCGS module
There are usually two types of integrative gene expression data illustrated in Figure 2 . Each of them contains many splices of sources/experiments or samples/patients, and each splice consists of two dimensional (2D) gene-sample data or 2D gene-time data. Specifically, Figure 2 (A) represents the genesample-source data [12] , in which the expression values for different samples from different sources have been collected for each gene, while Figure 2 (B) shows the gene-time-sample data [13] , where expression values across different time points under different samples are monitored for each gene. Therefore, both kinds of integrative gene expression data can be represented by a unified triplet. For simplicity, the gene-time-sample data is used as the example to illustrate our proposed method.
Let genes G = (g 1 , g 2 , ..., g |G| ) (|G| is the number of genes), sources S = (s 1 , s 2 , ..., s |S | ) (|S | is the number of samples), and time points T = (t 1 , t 2 , ..., t |T s | ) (|T s | is the number of measured time points for sample s). Similar to [11] (1), (2) and (3) simultaneously.
where, i = 1 or 2; < e G m sT >=
, named average module trajectory, is the average expression profile over all genes in G m for sample s; ρ is the distance related to correlation coefficient r by the simple formula ρ = 1 − r; τ G , τ S are two thresholds for positive correlations; and τ is the negative correlation thresholds.
Equation (1) constrains that a gene should follows the similar profiles to the average module trajectories of the gene subset it belongs to over all samples though the profiles in different samples do not need to be similar; and equation (2) promises that for any sample in the NCGS module, genes within the same subset have similar behaviors. Therefore, Equation (1) and (2) together state that genes within the same gene subset of the NCGS module are positively correlated for every sample. Equation (3) shows that for every sample, the two different gene subsets are negatively correlated.
To compute the correlation r, we do not follow [11] which uses Pearson's Correlation Coefficient (PCC), for PCC focuses on numerical correlations [14] regardless of the profiles, which results that two dissimilar profiles may have high PCC correlation score. Instead, we adopt the Spearman Rank Correlation (S RC) to measure the trend correlations. The S RC between two vectors (gene expression profiles in our work) X = (x 1 , ..., x n ) and Y = (y 1 , ..., y n ) is given by equation (4):
Here, r X (x i ) and r Y (y i ) are the ranks of element x i in X, and element y i in Y respectively. The calculation of the element's rank is followed by: r X (x i ) = k ⇐⇒ |{ j|x j < x i }| = k − 1. Just like PCC, S RC has also been proved to be a bounded measurement as it satisfies −1 ≤ S RC(X, Y) ≤ 1 for all X, Y [14] , and positive (negative) values means positive (negative) correlations. Therefore, the parameter τ should be negative to promise the mining of negative correlations.
According to the definition of NCGS, genes in the module are always divided into two groups. On one hand, under each sample in the module, all genes from the same group show similar changing trends, while any of them may follow different/similar varying ways in different samples. On the other hand, any two genes from different groups show opposite expression tendencies in the same sample.
Though the definition of NCGS module is inspired by IR module [11] , it is different with IR module in two ways. The first and most important one is that there are two gene groups in a NCGS module, genes within the group are positively and between groups are negatively correlated. While all genes in a IR module belong to one group and have positive correlations; The second one is that S RC is used in NCGS, whereas PCC is used in IR. Thus, just mentioned above, S RC reflects the correlations between gene profiles more likely than PCC.
NCGS modules mining method: negEDISA
The framework of negEDISA
Now that EDSIA [11] was originally proposed to mine IR and other two kinds of modules by considering positive correlations, and NCGS is the extension of IR, we propose a NCGS module mining algorithm based on EDSIA in this section, called negEDSIA hereinafter. The framework of negED-SIA is illustrated in Figure 3 . First of all, the negEDISA optionally conducts a preprocessing procedure to filter out genes having small difference (no more than two folds) under at least one splice, with the purpose of removing noise signals and unaffected genes.
Similar to EDISA, ngeEDISA iteratively generates candidate modules one by one until the stopping criterion is satisfied. In each run, an initial module is first drawn from the data, which consists of k genes randomly drawn from the data without replacement and all of the conditions (The conditions represent for the samples for gene-time-sample data and sources for genesample-source data respectively). Then negEDISA refines gene and condition sets by repeatedly removing genes and conditions not sufficiently positively correlated with the average expression pattern of the module until the positively correlation is satisfied for all genes and conditions.
Since negEDISA produces candidate modules by random sampling and refining, there may be several copies of the same modules or the module and its submodules in the results after above iteration steps. The merging step is then needed to remove these redundant modules.
There are only positive correlations in the remaining modules (IR modules), and the number of involved genes and conditions may not be maximal. Therefore, for each of such module, negEDISA first adds negative correlated genes into the modules; and then extends both genes and conditions to promise the maximality; finally, to keep the balance of two negative correlated gene sets, a multi-objective evolutionary algorithm NSGA-II [15] with six objective functions is used to avoid trivial NCGSs whose two gene groups' size are too unbalanced.
After of all, the redundancy of final modules is also removed to guarantee any two remaining modules have no more than 75% overlap with each other on both genes and conditions.
Besides using SRC instead of PCC, the difference of negEDISA is that it uses two additional steps to mine NCGSs originating from IR modules: the adding negative correlated genes step and balancing step. Therefore we only introduce these two steps in the following, and the details of other steps can be seen in [11] .
Extending IR module by adding negative correlated
genes We still adopt gene-time-sample to illustrate the idea of extending IR. Suppose G, T and S are the gene, time point and sample sets of the integrative dataset (G, T, S ) respectively, and
, the extending algorithm is listed in Algorithm 1. For every gene in G IR , it simply checks every gene outside of G IR and puts those significantly negative correlated genes into the module.
Algorithm 1 Extending IR module to NCGS module
for s in S IR do 5:
if r(e ge sT , e gn sT ) < τ then 6:
end
Balancing the negative gene sets by MOEA
The module generated by the extending step consists of two gene sets, the first one is the original one from the IR module, and the second one is composed of those having negative correlation with at least one gene in the first one under at least one sample. However, these two sets may be not negatively correlated, or the sizes of them are unbalanced. In order to get non-trivial NCGS modules, we optimize every module by using NSGA-II algorithm [15] .
In order to use NSGA-II, we need to encode the individuals in the population, and to define the objective functions. Given
an individual of the population is restricted to be a subset of G 1 ∪ G 2 and is encoded as a binary string with length m 1 + m 2 , where the former m 1 bits represent for a subset of G 1 and the later m 2 bits represent for a subset of G 2 , and "1" stands for the specific gene is in the subset whereas "0" denotes that it is not in the subset. Since the former m 1 bits and the later m 2 bits correspond to two different gene sets in the module, we constrain that the crossover between two individuals only operates on the corresponding segments.
Suppose the gene subset involved in an individual bẽ G 1 ∪G 2 , in order to get the balanced negatively correlated gene sets, we define the following six objective functions to be optimized (minimized):
Where, minimizing f 1 and f 2 ensures that genes within each set are positively correlated; minimizing f 3 promises two sets are negatively correlated; minimizing f 4 and f 5 requires both gene sets are maximal; and minimizing f 6 tries to keep two sets balanced.
By setting the generation number to 1000, and other parameters as default values of NSGA-II, we can get the optimized NCGS modules which will be used to construct the classifiers.
Encoding gene modules to construct the classifiers for
cancer prognosis In this paper, LibSVM [16] is used to construct the classifiers for predicting the cancer prognosis. Thus, the gene modules are input features of SVM. As mentioned above, there are two kinds of 3D gene expression data. The gene-time-sample data can supply genetic information (gene expressions in dynamic status) of only one group of patients, whereas the gene-samplesource data gives more independent groups of patients with less genetic information. Therefore, different technologies have to be applied to encode their modules into numerical values separately.
Gene module encoding for gene-time-sample data
In the gene-time-sample data, illustrated in Figure 2 (B), each sample is related to a gene-time 2D data, which can thus provide many genetic clues for the classification. Therefore, the coherence measurement of genes is used as the numerical encoding. Here, our recently proposed MMSE scoring (under publication and proof is omitted) is tried in this work for it can consistently measure both positive and negative correlations and is more general and robust than other measurements. Given a gene module D with gene set G and time point set T , its MMSE score under sample s is given by equation (11):
where, e gst denotes the expression value of gene g at time point t under sample s, λ max (E) is the largest eigenvalue of square matrix E, and E = (e i, j = ∑ t∈T e ist e jst ) |G|×|G| . Figure 2(A) , the gene-sample-source data contains multiple splices of gene-sample 2D data, which means, given the genes, their expression values can be collected in different groups of samples from dissimilar sources. Although there is no evolutionary information in such data, it is expected that genes in the same module are involved in the related functions. Therefore, the functional significance values of the gene modules in each sample are calculated by enrichment analysis, similar to [8] , and use the P-values as their encodings.
Gene module encoding for gene-sample-source data Illustrated in
Experiment results and discussion
We have conducted evaluation experiments on gene-timesample data and gene-sample-source data respectively. In each experiment, we ran both negEDISA and the original EDISA on the same data sets to get NCGS modules and IR modules separately. In order to get more modules, we ran them several times by using different threshold values, that is, τ S and τ G were both set experientially from 0.1 to 0.9 with step 0.1, and τ as -0.1 (disregarded in EDISA).
For either of the data, we used different kinds of methods to choose biomarkers from the mined gene modules: (a) only using the IR modules mined by EDISA (denoted as P); (b) only using NCGS modules mined by negEDISA and regarding one NCGS as a whole (denoted as N); (c) only using NCGS modules but regarding two negative correlated gene subgroups as two biomarkers (denoted as N2); (d) using all gene modules and regarding one NCGS as a whole (denoted as PN); (e) using all gene modules but regarding two negative correlated gene subgroups in NCGS as two biomarkers (denoted as PN2).
All the classification models have adopted the same method SVM with linear kernels but different feature extraction methods. We used P-values (same calculation method as [17] , and the significance thresholds used in enrichment analysis adopting 20% significant over-expressed genes or down-expressed genes by experience) and MMSE scores to encode the gene modules for gene-sample-source and gene-time-sample data respectively.
Experiment on gene-time-sample data of IFNβ response
A clinical gene-time-sample data, noted as MS-data, was obtained from the study of transcription-based prediction of response to IFNβ in [18] . This data set contains pre-selected 70 genes relevant to relapsing-remitting multiple sclerosis (MS), and 52 MS patients. By treating with IFNβ, 33 of the patients have good prognosis and the other 19 belong to poor prognosis. In order to study the transcription response of the treatment, the genes' expression profiles on 7 time points (0, 3, 6, 9, 12, 18 and 24 months after the treatment) were measured for every patient, and the possible missing measurements of some patients were filled with zero.
To investigate whether and how NCGS modules can improve the cancer prognosis accuracy, our experiment results have been compared with the results of SVM in previous study [18] . As done in [18] , different prediction models will be built on sub gene expression data (taking logarithm transformation) at first T sampling time points (T=2, 3,. .., 7 points), for the best time points to supervise IFNβ response is not convinced. For markers from either of P, N, N2, PN and PN2, the BFS (Backwards Feature Selection) was used to select the most distinguishable modules from the top 30 ones measured by BSS/WSS [19] ; and the related SVM classifiers were built on the MMSE coding of the selected markers by LibSVM package [16] . The resulting classifiers are correspondingly noted as SVM-P, SVM-N, SVM-N2, SVM-PN and SVM-PN2. Moreover, in order to compare with [18] (its classifier is simply denoted as SVM), 4-fold cross-validation method is also used in our experiments. The comparison result is shown in Figure 4 . Figure 4 we can see, first, the gene markers extracted by negEDISA method can enhance the prediction accuracy of prognosis classifiers. Secondly, SVM-N is close and SVM-N2 is even superior to original SVM by using different features, showing that negative information coded in SVM-N or SVM-N2 indeed has its values in cancer studies. Thirdly, the SVM-N2 being better than SVM-N further demonstrates that considering two negative correlated gene sub-groups in NCGS modules separately may be a more acceptable feature production strategy.
We also notice that, although both N2 and P consider the positively correlated genes as the biomarkers, two different markers corresponding to negatively correlated gene sets always occur in couple while P can not promise the couple appearance of negatively correlated gene sets; moreover, each of the gene sets in N2 is more compact due to the balancing procedure while the gene sets in P are usually more larger than N2 due to the maximal preference of EDISA. The fact that SVM-N2 is significantly better than SVM-P (In fact, SVM-P and SVM-N, SVM show almost equal performances) shows that using the compact negatively correlated gene sets in pairs is more reasonable than the use of single maximal set when constructing the classification models.
Finally, the fact that the SVM-PN2 is the best among other classifiers integrated with markers from P, N and N2 illustrates that NCGS modules solely will be not enough in cancer prognosis. It is applicable to combine positive markers elsewhere.
Experiment on gene-sample-source data from collected six sources of breast cancer
The gene-sample-source data of breast cancer, noted as BRC6-data, is collected from six sources of NCBI GEO with access id GDS2250 [20] , GDS807 [21] , GDS2415 [22] , GDS360, GDS1329 [23] and GDS2635 [24] . For GDS1329 is a three-classes dataset, it is transformed into three two-classes datasets by assigning one class as positive and the other two as negative, and these datesets are denoted as GDS1329-A, GDS1329-B, GDS1329-C respectively. All datasets have the same 5840 genes, and details of the sample compositions in differeent data sets are listed in Table 1 . GDS2250  47  7  40  GDS807  60  32  28  GDS2415  59  31  28  GDS360  24  14  10  GDS2635  30  20  10  GDS1329-A  49  6  43  GDS1329-B  49  16  33  GDS1329-C  49  27  22 In this experiment, Leave-One-Out Cross-Validation (LOOCV) method was applied to evaluate the classification performances. In order to investigate whether the extracted gene modules are full of functional meaning to distinguish cancer status, P-values of KEGG pathways [25] that are expected to be related to specific biological procedures, were also used to build the gold standard classifiers. The experimental results are listed in Fiture 5.
It can be seen again that considering both positive and negative correlated gene sets can usually get better classification performance than only considering either positive or negative correlated gene sets. In addition, from the comparison between SVM-KEGG and SVM-PN/SVM-PN2 we can see that the later methods are comparable to the former one on most of the data sets. As it is known to all, extensive biological experiments are Thus the computational detected gene modules are more suitable for biomarker discovery in real applications. All in all, NCGSs are novel viewpoints of gene markers dissimilar to existing functional gene groups. They obtain competitive results in the exploring experiments here, and have expectable potential to further promote cancer prognosis ability by combing with other gene set's activity measurements [8] .
Biological investigation on NCGS modules
Since the genes in MS-data have already been filtered to only remain the MS relevant ones, we check the genes in NCGS modules mined from BRC6-data to investigate their relevance to breast cancer in this section.
In order to understand the relationship between NCGS modules and pathogen mechanism of breast cancer, we choose one of the NCGS modules with significant negative correlation (with correlation values 0.25, 0.2 and -0.8 calculated by equation (1), (2) and (3) respectively) as an example, noted as Ω and shown in Table 2 . The profiles of the genes in Ω are illustrated in Figure 6 . From Figure 6 , these gene set pair of Ω shows distinct negative correlated gene expression profiles on samples in data sets GDS2250 and GDS1329. In fact, all of the four genes in Table 2 are known to be important in breast cancer development: NFIL3 has its specific and essential role for the development of NK cells possibly related to tumor cell growth and metastasis in breast cancer [26] ; ART3 acts as tumor-rejection antigen that possess tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes (CTLs) in cancer patients [29] ; DNALI1 had been found to be close neighbour of several breast cancer "causal genes" as ESRI, GATA3, FOXAI, and AR [27] ; AGR2 is a metastasis inducing protein with significant effect on breast cancer patient survival [28] . (1), (2) and (3) respectively), which is noted as Ψ and shown in Table 3 . By functional enrichment analysis on gene sets in Ψ, we found that Gene set 1 is biologically significant on Biological Process, Cellular Component and KEGG Pathway.
For Biological Process, 14 genes are covered by response to stimulus (GO:0050896) with P-value 3.45e-06; 11 genes are covered by immune system process(GO:0002376) with Pvalue 5.07e-10; and 11 genes are covered by signal transduction (GO:0007165) with P-value 2.96e-05.
For Cellular Component, 12 genes are covered by cell periphery (GO:0071944) with P-value 3.12e-06, and 12 in 15 genes are covered by plasma membrane (GO:0005886) with P-value 2.50e-06; For KEGG Pathway, three genes are covered by Natural killer cell mediated cytotoxicity (KEGG:04650) with P-value 1.37e-03, and three genes are covered by Osteoclast differentiation (KEGG:04380) with P-value 8.02e-04. From the literatures, it is known that NK cells are effective mediators of anti-tumour responses in the way of cytotoxic granule killing or apoptosis-inducing pathways [30] , and during the development of progestin-driven mammary cancer like breast cancer, Osteoclast differentiation factor will be a key to control [31] .
Although Gene set 2 show less significant biological functions in enrichment analysis, it has been shown that that TFPI2 (tissue factor pathway inhibitor 2) is some protease inhibitor which usually can be up-regulated in human tumor like breast cancer [32] ; The peptides of RGS5 (regulator of G-protein signaling 5) can be vaccines candidates to target malignant cells and tumor vessels [33] ; And loss of PCDH8 (protocadherin 8) expression is thought to lead the possible loss of heterozygosity, partial promoter methylation, and increased proliferation [34] .
All above facts suggest that most genes in NCGS module Ψ are indeed relevant to breast cancer either through the way of biological network or by their specific molecular function influence on other genes/proteins. Therefore, Ψ indicates the significant biological functional relationship to breast cancer even though it has relaxed numeric characteristic according to NCGS definition.
We also try to build the linkages between two genes in Ψ by CCancer spider tool, which automatically collects gene lists reported frequently in previous biological and clinical experiment contexts [35] . For the genes in Ψ, the gene pairs which were frequently reported together by other biological studies, are included in the gene association network as displayed in Figure  7 . This result from third analysis tool supports again NCGS module Ψ has strong pathogen relevance.
At present, the causal relation between those two negative correlated gene sets in Ψ is still not clear. Combined with above gene functional information, we can guess that TFPI2 seems to be responsible for efficient protein transduction through the plasma membrane [36] , thus TFPI2 in gene set 2 maybe have compensate expression behavior with proteins in plasma membrane where the proteins from gene set 1 fully locate. This is possible an equilibrium mechanism during biological signal transduction which needs help from wet experiments to validate in future.
Anyway, in the computational aspect, NCGS can provide a natural strategy to obtain two (or one) compact positive correlated gene sets by requiring their negative correlation in balance, and suggest candidate causal relation between these two negative correlated gene sets. That's why NCGS can promote the study of cancer prognosis as shown in our experiments.
Conclusion
In this paper, we first presented the formal definition of negative correlated gene set (NCGS), then proposed an advanced negEDISA method to mine NCGS modules from integrative gene expression data, and finally made use of the negative correlation information of NCGSs in the prediction of cancer prognosis. Experimental results on both gene-time-sample and gene-sample-source data show that the negative correlated genes as well as the traditional maximal positive correlated genes can improve the prediction accuracy. This work mainly focuses on the exploring application of NCGS modules in cancer prognosis. In the future, we will investigate the expanded applications of NCGS modules on the mechanism of cancers and gene regulation programs. 
